Evidence map›Paper›PMID 36284634›Full record

ArticleJournal of oncology2022

Overexpression of Laminin 5

Chengyi Yin, Bingliang Ma, Xilin Zhang, Longjiang Lan, Gang Ren, Jue Xu, Jianqiu Wang

Open access · hybridAbstract read
In one paragraph

Article in Journal of oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Chengyi YinDepartment of Otolaryngology, The First Affiliated Hospital, Huzhou University, The First People's Hospital of Huzhou, Huzhou City, Zhejiang Province, China.ORCID https://orcid.org/0000-0002-1461-4244
Bingliang MaDepartment of Otolaryngology, The First Affiliated Hospital, Huzhou University, The First People's Hospital of Huzhou, Huzhou City, Zhejiang Province, China.
Xilin ZhangResearch Department, The First Affiliated Hospital, Huzhou University, The First People's Hospital of Huzhou, Huzhou City, Zhejiang Province, China.
Longjiang LanDepartment of Otolaryngology, The First Affiliated Hospital, Huzhou University, The First People's Hospital of Huzhou, Huzhou City, Zhejiang Province, China.
Gang RenDepartment of Otolaryngology, The First Affiliated Hospital, Huzhou University, The First People's Hospital of Huzhou, Huzhou City, Zhejiang Province, China.
Jue XuDepartment of Otolaryngology, The First Affiliated Hospital, Huzhou University, The First People's Hospital of Huzhou, Huzhou City, Zhejiang Province, China.
Jianqiu WangDepartment of Otolaryngology, The First Affiliated Hospital, Huzhou University, The First People's Hospital of Huzhou, Huzhou City, Zhejiang Province, China.ORCID https://orcid.org/0000-0003-0501-7410
Huzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Laryngeal squamous cell carcinoma (LSCC) is a common malignant tumor. Laminin 5 Methods: The level of LAMC2 in 46 LSCC patients was detected by qRT-PCR and western blot. Then the relationship between LAMC2 expression and LSCC malignancy as well as prognosis was analyzed, and the effect of LAMC2 expression on LSCC patient survival was also analyzed using the Kaplan-Meier survival curves. Afterwards, the LSCC cells were transfected with LAMC2 overexpression and knockdown vectors, the effect of LAMC2 on LSCC cell viability, proliferation ability, cell cycle, cell migration, and invasion were detected by CCK-8, colony formation, flow cytometry, wound healing, and Transwell assays. The expression of EMT-related biomarkers and integrin Results: LAMC2 was expressed at high level in LSCC tissues and associated with poor prognosis. LAMC2 overexpression increased TU177 cell viability, proliferation ability, promoted cell cycle, cell migration, and invasion capacity. The expression of N-cadherin, vimentin, and integrin Conclusion: The findings suggested that LAMC2 was overexpressed in LSCC and correlated with poor prognosis. LAMC2 knockdown inhibited LSCC progression by regulating the integrin

Identifiers

PMID36284634
PMCPMC9588344
OpenAlexW4306313789

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.